Real-World Clinical Data: Shaping Evidence-Based Decision-Making In Diabetes Dosage Forms Powered By Natural Compounds

Recent enhancements in the methodological rigor of real-world studies and the increased availability of higher-quality, comprehensive datasets have amplified the importance of findings from these investigations. Recognizing this, regulatory bodies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have acknowledged the significance of real-world data in supporting marketed products and contributing to product development and monitoring throughout their lifecycle. Moreover, national and regional healthcare bodies, such as the UK's National Institute for Health and Care Excellence (NICE) and Germany's Institute for Quality and Efficiency in Health Care (IQWiG), utilize real-world data for guiding clinical decision-making [4,5]. Payers also increasingly rely on such data to inform decisions, particularly in utilization management and formulary placement.